AidaBREAST Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

Novel assay developed on Akoya PhenoImager HT platform with Opal chemistry becomes first to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.

Apr. 17, 2026 at 12:34pm by

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the intricate internal structures of a breast cancer tumor, conveying the advanced analytical capabilities of the AidaBREAST assay.A groundbreaking new diagnostic tool harnesses the power of spatial proteomics to provide unprecedented insights into breast cancer biology and treatment response.San Francisco Today

PreludeDx and Quanterix Corporation announced that AidaBREAST, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on the Akoya PhenoImager HT platform using Opal chemistry. This marks a significant milestone in the clinical translation of spatial proteomics. The validation of AidaBREAST included 922 hormone receptor-positive, HER2-negative invasive breast cancer patients across four academic and clinical centers in the United States and Sweden, with a median follow-up of ~10 years.

Why it matters

AidaBREAST leverages spatial biology and AI to provide unique insights into the tumor and immune-microenvironment, giving oncologists a tool that can not only predict a patient's likelihood of recurrence, but also whether radiation therapy will benefit that specific patient. This represents a meaningful shift in how treatment decisions can be informed.

The details

The AidaBREAST assay integrates spatial multiplex protein expression data obtained using the PhenoImager HT platform and Opal chemistry, with targeted next-generation RNA sequencing, to provide a comprehensive assessment of tumor biology. This approach enables the assay to be both prognostic for 10-year locoregional recurrence risk and predictive for radiation therapy benefit, capabilities not previously available in a single test for early-stage invasive breast cancer.

  • The validation of AidaBREAST included 922 hormone receptor-positive, HER2-negative invasive breast cancer patients across four academic and clinical centers in the United States and Sweden, with a median follow-up of ~10 years.
  • Dr. Karuna Mittal will present the AidaBREAST study findings at the Quanterix booth 2028 at the AACR Annual Meeting 2026 on Tuesday, April 21st from 11:45 to 12:00 PM.

The players

PreludeDx

A leading personalized breast cancer diagnostics company serving patients and physicians worldwide, founded in 2009 with technology from the University of California San Francisco.

Quanterix Corporation

A global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company.

Karuna Mittal, PhD

Senior Director of Research and Development at PreludeDx and co-author of the published study on AidaBREAST.

Everett Cunningham

Chief Executive Officer of Quanterix.

Akoya PhenoImager HT

A platform developed by Akoya Biosciences that enables spatial proteomics.

Got photos? Submit your photos here. ›

What they’re saying

“AidaBREAST harnesses the power of spatial biology and AI to provide unique insights into the tumor and immune-microenvironment not available from clinicopathology. For the first time, oncologists have a tool that tells them not just how likely a patient is to recur, but whether radiation therapy is actually going to help that specific patient. That is a meaningful shift in how we can better inform treatment decisions.”

— Karuna Mittal, PhD, Senior Director of Research and Development at PreludeDx

“AidaBREAST is exactly the kind of scientific achievement that demonstrates what is possible when spatial proteomics is applied with rigor and clinical intent. PreludeDx's ability to develop a truly novel tool on our PhenoImager HT platform – that also performs reliably and reproducibly across multiple institutions and years of archived tissue, speaks to the immediate opportunity for spatial proteomics in clinical oncology.”

— Everett Cunningham, Chief Executive Officer of Quanterix

What’s next

Dr. Karuna Mittal will present the AidaBREAST study findings at the Quanterix booth 2028 at the AACR Annual Meeting 2026 on Tuesday, April 21st from 11:45 to 12:00 PM.

The takeaway

AidaBREAST represents a significant advancement in precision oncology, leveraging spatial proteomics and AI to provide clinicians with a comprehensive tool that can predict both recurrence risk and radiation therapy benefit for early-stage invasive breast cancer patients. This innovation has the potential to transform treatment decision-making and improve outcomes for breast cancer patients.